Lilly poised for windfall following FDA approval of Cialis for BPH indications
This article was originally published in Scrip
Executive Summary
Eli Lilly is poised to benefit from a windfall after FDA granted marketing authorisation for once daily Cialis (tadalafil) to treat men with BPH symptoms alone or with both BPH and erectile dysfunction. This is the first drug to offer this convenient option to patients. These new indications will provide Eli Lilly with an estimated additional $150m in annual sales for Cialis in the US.